The cannabis sector consists of 5 distinct categories and they each performed quite differently from each other during the third week of May.

During the second week of May, two of the 5 categories we index showed some improvement; here, the numbers for all the stocks in all 5 categories for last week, YTD and from the 2021 peak.

We're tracking 13 public companies (US and/or Canada) doing clinical-stage research into THC and/or psychedelics for treating mental illnesses. While a few were up this week, the overall trend continues downward.

The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week.

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.